MedTrace Logo

The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

NCT07211126 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2026-05-01

No results posted yet for this study

Summary

This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DEVICE

t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)

Participants enrolled in the study will start use of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with Dexcom G6 or Dexcom G7, and be followed for 12 months.

Sponsors & Collaborators

  • Tandem Diabetes Care, Inc.

    lead INDUSTRY

Principal Investigators

  • Jean-Pierre Riveline, MD, PhD · Centre Universitaire du diabète et de ses complications, APHP, Hôpital Lariboisière, Paris, France

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-03
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Device
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07211126 on ClinicalTrials.gov